Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have at least one chronic non-healing Wagner Grade 1 or Grade 2 plantar neuropathic diabetic ulcer between 1.0-6.0 cm2 on the midfoot or forefoot, including the toes but excluding the heel.~* ABI greater than 0.7 for neuroischemic or greater than 0.8 for neuropathic DU~* TcPO2 greater than 40 mm Hg or great toe systolic pressure greater than 50 mmHg~* Type I or Type II diabetes under metabolic control~* Female subjects must have a negative pregnancy test and be willing to use acceptable method of birth control for the duration of the study~Exclusion Criteria:~* Exposure to any investigational product within the last 30 days, or have known hypersensitivity to any of the study medication components~* Chronic renal insufficiency and/or chronic liver dysfunction~* Resting blood pressure (at the time of the initial visit of the Screening Period) which exceeds 160 systolic and/or 90 diastolic mmHg on 3 consecutive readings at least 15 minutes apart~* Malignancy of any kind~* Receiving hemodialysis or CAPD~* Current history of drug abuse, and/or known to be HIV positive~* Prior radiation therapy of the foot under study~* Current use of corticosteroids (within past 8 weeks), immunosuppressants (within past 8 weeks), or use of a biologic agent to include growth factors and skin equivalents (Regranex, Apligraft, or Dermagraft) in the past 90 days~* Ulcer is deemed clinically infected and requires topical antimicrobials or agents known to affect wound healing, or the subject has been taking systemic antibiotics for more than 7 days for any reason~* Sickle-cell anemia, Raynaud's or other peripheral vascular disease~* Wagner Grade 3 or higher DU, deep abscess or infection of the joint or tendon, or gangrene or osteomyelitis~* An EKG with a marked baseline prolongation of QT/QTc interval

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo Vehicle Control (Type: PLACEBO_COMPARATOR): control placebo vehicle gel
- 0.03% DSC127 (Type: ACTIVE_COMPARATOR): 0.03 % DSC127 in Vehicle Control
- 0.01% DSC127 (Type: ACTIVE_COMPARATOR): 0.01% DSC127 in Vehicle Control

Based on this trial design, predict the completion outcome and termination type (if applicable).